Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of “Moderate Buy” from Analysts
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price […]
